Article Text

Download PDFPDF
EP309 Survival analysis in advanced cervical cancer
  1. M Hernandez Ontoria,
  2. A Vázquez Sarandeses,
  3. G López González and
  4. Á Tejerizo Garcia
  1. Gynecology and Obstetrics, Hospital 12 Octubre, Madrid, Spain


Introduction/Background To assess the survival in advanced cervical cancer treated with external beam radiation (EBRT) concurrent chemotherapy (CT) followed by brachytherapy (BT).

Methodology Retrospective unicentric study which includes patients with advanced cervical cancer treated with (EBRT) concurrent chemotherapy followed by brachytherapy between 2010 and 2017. Survival analysis was obtained by Kaplan-Meier and logrank test. SPSS 21.

Results The mean age among the 79 patients studied was 54,75 (SD 14,52) years. The mean tumour size was 53,37 (SD 17,47) mm. The first line of treatment was EBRT with concurrent CT followed by BT in 83,5% of the cases and EBRT or CT in monotherapy 3,8% and 12,6% respectively. 35,3% of the patients received a second line of treatment. Epidermoid carcinoma (64,6%) was the most frequent histological type. According to the stage (FIGO 2016) these groups were observed: 10,1% IB2, 10,1% IIA, 43,0% IIB, 2,5% IIIA, 12,7% IIIB, 21,5% IV.

After a year, overall survival was 81,0% and at five years was 67,1%. According to histological type, the five-year overall survival rate was: 74,5% epidermoid carcinoma, 66,7% adenocarcinoma, 50% adenosquamous carcinoma, 20% undifferentiated carcinoma. Significant differences were found (p=0,013) in survival curves between histological group of epidermoid/adenocarcinoma vs undifferentiated. Overall survival in five years according the stage was: 75,0% IB2; 87,5% IIA; 76,5% IIB; 50,0% IIIA; 40,0% IIIB y 52,9% IV.

Conclusion The survival results were similar to others found in the literature, except for the most advances stages what could be explain for the limited sample size.

Histological type was a determining factor in the survival of cervical cancer.

In the light of the results of the study it was found a considerable percentage of patients needed a second line of treatment.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.